Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effecti ...

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates.

Acute ischemic stroke, which occurs due to a blockage in cerebral blood flow, requires prompt intervention with thrombolytic ...

No significant difference seen in terms of effectiveness or safety outcomes, including functional independence at discharge. (HealthDay News) — For patients with ischemic stroke, tenecteplase ...

A new clot-busting drug for stroke works as well as a decades-old drug Patients given tenecteplase had similar outcomes to ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Genentech said in a press release that TNKase (tenecteplase) has been approved as a one-time, 5-second IV bolus. It is the second FDA-approved treatment for acute ischemic stroke, the other being ...